The main cause of occupational and social activity disorders in patients with multiple sclerosis (MS) is motor deficit. The genesis of movement disorders reflects multifocal lesions of various parts of the spinal cord and brain. The patient groups were formed according to the EDSS scale: with mild (EDSS 2,5–4,0 b), moderate (EDSS 4,5–5,5 b) and severe motor disorders (6,0–6,5 b). There was performed neurological examination of patients with an assessment of the cognitive and vestibular functions of the body. The dominant syndromes in the development of motor disorders are central paresis, focal, pelvic and cognitive impairments. The developed complex of rehabilitation measures with the use of a stabilometric complex, a treadmill and physiotherapeutic treatment, made it possible to improve the motor function in patients with multiple sclerosis at all stages of the disease. These measures were implemented in the Republican Clinical and Diagnostic Center for demyelinating diseases in Kazan.

The purpose — to clarify the clinical and epidemiological characteristics of multiple sclerosis (MS) in the Republic of Tatarstan (RT). Material and methods. A retrospective analysis of the register of MS patients in RT from 2015 to 2019 was carried out. The sample size was 2351 patients. The type of MS course, disease duration, clinical characteristics, including EDSS and MSSS scores, used by disease modifying therapies (DMT) were analyzed. Results and conclusions. The prevalence of MS in RT continues to grow and has increased by 29% over a 5-year period (from 46,6 to 60,3 per 100,000 population in 2015 and 2019, respectively). The incidence has relatively stabilized and averages 4,2 cases per 100,000 population per year. The dominant type of MS course in RT is remitting (51,3%), patients with progressive forms account for 48,7%, including those with primary progressive MS (6,9%). In RT, a positive tendency towards a more favorable course of the disease with a decrease in the degree of patients’ disability was traced, mainly due to early diagnosis and timely prescription of adequate treatment with DMT. The problem of timely diagnosis of MS in children and adolescents and in the primary progressive course of MS remains.

УДК 615.8:616.8ДВИГАТЕЛЬНЫЕ НАРУШЕНИЯ У БОЛЬНЫХ РАССЕЯННЫМ СКЛЕРОЗОМ Ахмедова Г.М. 1 , Сабиров Ж.Ф. 1 , Якупов М.А

AIM To evaluate the efficacy and safety of the interferon beta-1b bioanalogue 'infibeta' in the treatment of multiple sclerosis (MS) in comparison with other interferon beta bioanalogues and the generic drug glatiramer acetate. MATERIAL AND METHODS The data of 500 patients with MS treated with different disease-modifying drugs were analyzed. Patients of group 1 (n=95) received infibeta; group 2 (n=108) interferon beta-1b; group 3 (n=83) genfaxon-44; group 4 (n=109) sinnovex; group 5 (n=105) aksoglatiran FS. RESULTS In all groups, there was a significant decrease in the AARR and an increase in the EDSS score (p<0,05) after 12 and 24 months of treatment (p<0,05) with the best indicators in groups 1-3. After 12 months of treatment, the number of patients without signs of MRI activity was higher in groups 1-3 (48-61%) than in groups 4 and 5 (47, 43%, respectively) (p>0,05). After 24 months of treatment, the number of patients without signs of MRI activity decreased to 41-46% in groups 1-3, and more significantly in group 4 (27%). The percentage of NEDA-3 achieving patients did not significantly differ in the groups (23-32%) after 12 months of treatment. After 24 months of treatment the NEDA-3 declined more in group 4 (19%), least of all in groups 1 and 2 (27, 25%, respectively) (p>0,05). In most cases, the observed adverse events were mild or moderate. Flu-like syndrome was observed rarely in groups 1 and 4 (p<0,05). Injection reactions were observed most commonly in groups 3 and 5 (p<0,05). CONCLUSION Infibeta, while retaining all the advantages of high-dose interferon beta, has the best tolerability profile, which makes it one of the optimal first line disease-modifying therapy for treatment of patients with MS.